<DOC>
	<DOC>NCT00676741</DOC>
	<brief_summary>The study is conducted in Europe. The aim of this observational study is to evaluate the blood glucose control in patients using a modern insulin: NovoRapid®, NovoMix® 30 or Levemir® for the treatment type 2 diabetes. Full acronym for this study: COMMIT - CLEAN SWITCH</brief_summary>
	<brief_title>Observational Study on Blood Glucose Control in Patients With Diabetes Using Modern Insulin</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec, insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin aspart, insulin aspart protamine drug combination 30:70</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<mesh_term>Insulin Detemir</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin, Long-Acting</mesh_term>
	<mesh_term>Insulin, Isophane</mesh_term>
	<criteria>Patients with type 2 diabetes Patients treated with human soluble insulin, NPH insulin or premixed human insulin Patients willing to sign informed consent Selection of study participants at the discretion of the physician Subjects currently being treated with insulin aspart, insulin detemir or biphasic insulin aspart 30 Subjects who were previously enrolled in this study Subjects with a hypersensitivity to insulin aspart, insulin detemir or biphasic insulin aspart 30 or to any of the excipients</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>